[ad_1] The logo of Gilead Sciences pharmaceutical company is seen in Oceanside, California, April 29, 2020. Mike Blake | Reuters A Delaware federal court jury on Tuesday cleared Gilead Sciences of civil claims by the U.S. government that the company violated patents held by the Centers for Disease Control and Prevention for an HIV prevention…
[ad_1] A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Patrick Van Katwijk | Getty Images Shares of Novavax jumped more than 50% on Tuesday after the company unveiled promising new vaccine data and…
[ad_1] Director of the Centers for Disease Control Rochelle Walensky departs after testifying before the Senate Committee on Health, Education, Labor and Pensions on the All-Hazards Preparedness Act at the Dirksen Senate Office Building on Thursday, May 4, 2023 in Washington, DC. Kent Nishimura | Los Angeles Times | Getty Images CDC Director Dr. Rochelle…
[ad_1] People walk by a Covid-19 testing site at Times Square on May 12, 2022 in New York City. Liao Pan | China News Service | Getty Images The Centers for Disease Control and Prevention will have less data to track the spread of Covid-19 and new variants in the U.S. after the public health…
[ad_1] Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization (WHO), speaks during a news conference in Geneva, Switzerland, December 20, 2021. Denis Balibouse | Reuters The spread of Covid-19 is no longer a global public health emergency, the World Health Organization declared Friday. “For more than a year, the pandemic has been on a…
[ad_1] Thibaut Mongon, CEO of Kenvue Inc. a Johnson & Johnson consumer-health business, speaks during an interview with CNBC during his company’s IPO at the New York Stock Exchange (NYSE), May 4, 2023. Brendan McDermid | Reuters Kenvue CEO Thibaut Mongon is betting on brand and product innovation to drive growth at the newly spun-out…
[ad_1] Shares of Johnson & Johnson‘s consumer-health spinoff Kenvue jumped 20% in afternoon trading Thursday after its market debut on the New York Stock Exchange, making it the biggest U.S. IPO in more than a year. The new company opened at $25.53 per share after originally pricing its initial public offering at $22 Wednesday night,…
[ad_1] Moderna’s sign is seen outside of their headquarters in Cambridge, MA on March 11, 2021. Boston Globe | Getty Images Moderna on Thursday blew past estimates for first-quarter earnings and revenue, posting a surprise quarterly profit, despite lower demand for Covid vaccines, its only marketable product. The biotech company generated first-quarter sales of $1.9…
[ad_1] Johnson & Johnson products on a shelf in a store in New York. Lucas Jackson | Reuters Johnson & Johnson’s consumer health business Kenvue priced its IPO at $22 per share Wednesday, toward the high end of its stated range, in an upsized deal that would bring in about $3.8 billion. At that IPO price, the new company…
[ad_1] FDA Commissioner Dr. Robert Califf speaks at an event celebrating hearing aids being available over the counter at a Walgreens in Washington, D.C., Oct. 19, 2022. Nathan Posner | Anadolu Agency | Getty Images Food and Drug Commissioner Dr. Robert Califf praised results Eli Lilly announced Wednesday that a clinical trial showed its Alzheimer’s…
